Localized fibrous tumors (LFTs) of the pleura: clinical data, asbestos burden, and syntactic structure analysis applied to newly defined angiogenic/growth-regulatory effectors.
This study was performed to add clinical data, to introduce new markers, and to perform syntactic structural analysis on localized fibrous tumors (LFTs) of the pleura. The material comprised clinical data and processed sections obtained from 36 patients. The results achieved from quantitative imaging techniques and syntactic structure analysis were correlated with clinical data, including patients' habits (smoking), asbestos exposure, survival, and tumor recurrence. The disease caused increasing chest pain and dyspnea in 47% of patients. Exposure to asbestos was noted in 13 out of 36 patients, whereas smoking posed no major risk factor. Two patients developed a recurrent tumor after 8 and 42 months, respectively; none of the other patients died of this tumor disease within the follow-up period of maximal 212 months. The cases were clearly discriminated from mesotheliomas by the marker profile. Frequent expression of accessible ligands for endogenous lectins galectins-1 and -3, the expression of the angiogenic macrophage migration inhibitory factor (MIF), and the dense vascularization intimate a functional relationship. The proliferation index (Nv) was computed to be 1.6% in line with the balance of galectin expression. Abnormal p53 was expressed in only 19.4% of the cases. The diagnosis of LFT can be aided by quantitative assessment of vimentin, CD34, MIF, vascularization, and proliferation. Considering the galectin network, differential expression was noted with preference to effectors limiting growth and aggressiveness.
Kayser
Klaus
K
UICC-TPCC, Institute of Pathology, Charite, Berlin, Germany. klaus.kayser@charite.de
Trott
Jana
J
Böhm
Gerhard
G
Huber
Monika
M
Kaltner
Herbert
H
André
Sabine
S
Gabius
Hans-Joachim
HJ
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D001194:Asbestos / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008263:Macrophage Migration-Inhibitory Factors / Q000032:analysis; D008297:Male; D008875:Middle Aged; D018218:Neoplasms, Fibrous Tissue / Q000737:chemistry* / Q000175:diagnosis* / Q000473:pathology; D018919:Neovascularization, Physiologic; D010997:Pleural Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology; D014746:Vimentin
D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D008263:Macrophage Migration-Inhibitory Factors; D014746:Vimentin; D001194:Asbestos